Lineage Cell Therapeutics, Inc. Financing Cash Flow
Lineage Cell Therapeutics, Inc. (LCTX) reported Financing Cash Flow of $10.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Lineage Cell Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $4.47M.
- Lineage Cell Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $5.56M, a 10.25% increase year-over-year.
- Lineage Cell Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $20.38M, a 6.23% decline year-over-year.
- Lineage Cell Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.83M.
- Lineage Cell Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $26.95M, a 24.84% decline from fiscal 2024.
- Lineage Cell Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $35.86M, a 458.26% increase from fiscal 2023.
- Lineage Cell Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $6.42M, a 293.57% increase from fiscal 2022.
- Lineage Cell Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $1.63M, a 95.58% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $10.03M 10-Q · filed 2026-08-06 | $30.41M derived: sum of 3 quarters · filed 2026-08-06 | $32.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $5.56M 10-Q · filed 2026-05-12 | $25.94M derived: sum of 2 quarters · filed 2026-05-12 | $27.77M derived: sum of 3 quarters · filed 2026-05-12 | $27.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $20.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $22.21M derived: sum of 2 quarters · filed 2026-03-05 | $21.91M derived: sum of 3 quarters · filed 2026-08-06 | $26.95M 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.53M derived: sum of 2 quarters · filed 2026-08-06 | $6.57M 10-Q · filed 2025-11-06 | $28.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$307.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.74M 10-Q · filed 2026-08-06 | $26.47M derived: sum of 3 quarters · filed 2026-08-06 | $26.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $5.04M 10-Q · filed 2026-05-12 | $26.78M derived: sum of 2 quarters · filed 2026-05-12 | $26.77M derived: sum of 3 quarters · filed 2026-05-12 | $26.88M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $21.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $21.73M derived: sum of 2 quarters · filed 2026-03-05 | $21.84M derived: sum of 3 quarters · filed 2026-03-05 | $35.86M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $102.00K derived: sum of 2 quarters · filed 2025-11-06 | $14.12M 10-Q · filed 2025-11-06 | $14.11M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $105.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $14.13M 10-Q · filed 2025-08-12 | $14.11M derived: sum of 3 quarters · filed 2025-08-12 | $14.92M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $14.02M 10-Q · filed 2025-05-13 | $14.01M derived: sum of 2 quarters · filed 2025-05-13 | $14.81M derived: sum of 3 quarters · filed 2025-05-13 | $20.44M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $794.00K derived: sum of 2 quarters · filed 2025-03-10 | $6.42M derived: sum of 3 quarters · filed 2025-03-10 | $6.42M 10-K · filed 2025-03-10 |
| 2023-09-30 | $807.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $6.43M derived: sum of 2 quarters · filed 2024-11-14 | $6.44M 10-Q · filed 2024-11-14 | $6.56M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $5.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.63M 10-Q · filed 2024-08-08 | $5.75M derived: sum of 3 quarters · filed 2024-08-08 | $6.71M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.00K 10-Q · filed 2024-05-09 | $123.00K derived: sum of 2 quarters · filed 2024-05-09 | $1.09M derived: sum of 3 quarters · filed 2024-05-09 | $1.12M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $122.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $1.09M derived: sum of 2 quarters · filed 2024-03-07 | $1.12M derived: sum of 3 quarters · filed 2024-03-07 | $1.63M 10-K · filed 2024-03-07 |
| 2022-09-30 | $964.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $997.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.51M 10-Q · filed 2023-11-09 | $2.46M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $33.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $546.00K 10-Q · filed 2023-08-10 | $1.50M derived: sum of 3 quarters · filed 2023-08-10 | $5.22M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $513.00K 10-Q · filed 2023-05-11 | $1.47M derived: sum of 2 quarters · filed 2023-05-11 | $5.19M derived: sum of 3 quarters · filed 2023-05-11 | $16.48M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $954.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $4.67M derived: sum of 2 quarters · filed 2023-03-09 | $15.97M derived: sum of 3 quarters · filed 2023-03-09 | $36.93M 10-K · filed 2023-03-09 |
| 2021-09-30 | $3.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $15.01M derived: sum of 2 quarters · filed 2022-11-10 | $35.98M 10-Q · filed 2022-11-10 | $40.79M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $11.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $32.26M 10-Q · filed 2022-08-11 | $37.07M derived: sum of 3 quarters · filed 2022-08-11 | $61.63M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $20.96M 10-Q · filed 2022-05-12 | $25.78M derived: sum of 2 quarters · filed 2022-05-12 | $50.34M derived: sum of 3 quarters · filed 2022-05-12 | $50.84M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $4.81M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $29.37M derived: sum of 2 quarters · filed 2022-03-10 | $29.88M derived: sum of 3 quarters · filed 2022-03-10 | $29.86M 10-K · filed 2022-03-10 |
| 2020-09-30 | $24.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $25.06M derived: sum of 2 quarters · filed 2021-11-10 | $25.05M 10-Q · filed 2021-11-10 | $25.05M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $503.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $493.00K 10-Q · filed 2021-08-12 | $488.00K derived: sum of 3 quarters · filed 2021-08-12 | $567.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$10.00K 10-Q · filed 2021-05-13 | -$15.00K derived: sum of 2 quarters · filed 2021-05-13 | $64.00K derived: sum of 3 quarters · filed 2021-05-13 | $1.00K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | -$5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $74.00K derived: sum of 2 quarters · filed 2021-03-11 | $11.00K derived: sum of 3 quarters · filed 2021-03-11 | $617.00K 10-K · filed 2021-03-11 |
| 2019-09-30 | $79.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $16.00K derived: sum of 2 quarters · filed 2020-11-04 | $622.00K 10-Q · filed 2020-11-04 | $716.00K derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | -$63.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $543.00K 10-Q · filed 2020-08-06 | $637.00K derived: sum of 3 quarters · filed 2020-08-06 | $782.00K derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $606.00K 10-Q · filed 2020-05-07 | $700.00K derived: sum of 2 quarters · filed 2020-05-07 | $845.00K derived: sum of 3 quarters · filed 2020-05-07 | $5.75M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $94.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $239.00K derived: sum of 2 quarters · filed 2020-03-12 | $5.14M derived: sum of 3 quarters · filed 2020-03-12 | $5.77M 10-K · filed 2020-03-12 |
| 2018-09-30 | $145.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $5.05M derived: sum of 2 quarters · filed 2019-11-12 | $5.68M 10-Q · filed 2019-11-12 | $32.06M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $4.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $5.54M 10-Q · filed 2019-08-08 | $31.91M derived: sum of 3 quarters · filed 2019-08-08 | $36.91M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $633.00K 10-Q · filed 2019-05-09 | $27.01M derived: sum of 2 quarters · filed 2019-05-09 | $32.00M derived: sum of 3 quarters · filed 2019-05-09 | $36.93M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $26.38M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $31.37M derived: sum of 2 quarters · filed 2019-03-14 | $36.29M derived: sum of 3 quarters · filed 2019-03-14 | $55.39M 10-K · filed 2019-03-14 |
| 2017-09-30 | $4.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $9.91M derived: sum of 2 quarters · filed 2018-11-08 | $29.01M 10-Q · filed 2018-11-08 | $29.86M derived: sum of 4 quarters · filed 2018-11-08 |
| 2017-06-30 | $4.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $24.02M 10-Q · filed 2018-08-02 | $24.86M derived: sum of 3 quarters · filed 2018-08-02 | $37.07M derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-03-31 | $19.10M 10-Q · filed 2018-05-10 | $19.94M derived: sum of 2 quarters · filed 2018-05-10 | $32.15M derived: sum of 3 quarters · filed 2018-05-10 | |
| 2016-12-31 | $843.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $13.05M derived: sum of 2 quarters · filed 2018-03-15 | $32.78M 10-K · filed 2018-03-15 | |
| 2016-09-30 | $12.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $31.94M 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | $19.73M 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | $64.78M 10-K · filed 2018-03-15 | |||
| 2014-03-31 | $12.13M 10-Q · filed 2014-05-12 | $21.25M derived: sum of 2 quarters · filed 2014-05-12 | $21.25M derived: sum of 3 quarters · filed 2014-05-12 | $33.28M derived: sum of 4 quarters · filed 2014-05-12 |
| 2013-12-31 | $9.13M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $9.13M derived: sum of 2 quarters · filed 2014-03-17 | $21.15M derived: sum of 3 quarters · filed 2014-03-17 | $34.26M 10-K · filed 2014-03-17 |
| 2013-09-30 | -$165.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $12.02M derived: sum of 2 quarters · filed 2013-11-12 | $25.14M 10-Q · filed 2013-11-12 | $26.76M derived: sum of 4 quarters · filed 2014-05-12 |
| 2013-06-30 | $12.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $25.14M 10-Q · filed 2013-08-09 | $26.76M derived: sum of 3 quarters · filed 2014-05-12 | $27.04M derived: sum of 4 quarters · filed 2014-05-12 |
| 2013-03-31 | $13.11M 10-Q · filed 2014-05-12 | $14.74M derived: sum of 2 quarters · filed 2014-05-12 | $15.01M derived: sum of 3 quarters · filed 2014-05-12 | $15.03M derived: sum of 4 quarters · filed 2014-05-12 |
| 2012-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $1.90M derived: sum of 2 quarters · filed 2014-03-17 | $1.91M derived: sum of 3 quarters · filed 2014-03-17 | $1.91M 10-K · filed 2014-03-17 |
| 2012-09-30 | $271.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $286.55K derived: sum of 2 quarters · filed 2013-11-12 | $286.55K 10-Q · filed 2013-11-12 | $287.29K derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-06-30 | $14.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $14.80K 10-Q · filed 2013-08-09 | $15.53K derived: sum of 3 quarters · filed 2014-03-17 | $3.05M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-03-31 | $0.00 10-Q · filed 2013-05-10 | $733.00 derived: sum of 2 quarters · filed 2014-03-17 | $3.04M derived: sum of 3 quarters · filed 2014-03-17 | $3.17M derived: sum of 4 quarters · filed 2014-03-17 |
| 2011-12-31 | $733.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $3.04M derived: sum of 2 quarters · filed 2014-03-17 | $3.17M derived: sum of 3 quarters · filed 2014-03-17 | $3.86M 10-K · filed 2014-03-17 |
| 2011-09-30 | $3.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $3.17M derived: sum of 2 quarters · filed 2012-11-09 | $3.86M 10-Q · filed 2012-11-09 | $10.96M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-06-30 | $137.55K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $827.38K 10-Q · filed 2012-08-09 | $7.92M derived: sum of 3 quarters · filed 2013-03-18 | $17.55M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-03-31 | $689.83K 10-Q · filed 2012-05-10 | $7.78M derived: sum of 2 quarters · filed 2013-03-18 | $17.42M derived: sum of 3 quarters · filed 2013-03-18 | |
| 2010-12-31 | $7.09M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $16.73M derived: sum of 2 quarters · filed 2013-03-18 | $25.77M 10-K · filed 2013-03-18 | |
| 2010-09-30 | $9.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | $18.67M 10-Q · filed 2011-11-08 | ||
| 2010-06-30 | $9.04M 10-Q · filed 2011-08-09 | |||
| 2009-12-31 | $16.48M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |